AG˹ٷ

STOCK TITAN

[Form 4] HilleVax, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

HilleVax, Inc. (HLVX) filed a Form 4 disclosing that non-employee director Jaime Sepulveda received 17,199 restricted stock units (RSUs) on 23 Jun 2025 under the company’s Non-Employee Director Compensation Program. The RSUs carry a $0 exercise price and will vest 100% on the earlier of (i) the first anniversary of the grant date or (ii) a Change in Control, provided the director remains on the board through the vesting date.

Following the grant, Sepulveda’s total direct ownership increased to 59,224 common shares. No derivative securities were reported, and there was no open-market purchase or sale; this is an equity award intended to align director incentives with shareholder interests. The transaction does not materially affect HilleVax’s share count or capital structure, but it modestly increases insider ownership.

HilleVax, Inc. (HLVX) ha depositato un Modulo 4 comunicando che il direttore non dipendente Jaime Sepulveda ha ricevuto 17.199 unità azionarie vincolate (RSU) il 23 giugno 2025, nell'ambito del Programma di Compenso per Direttori Non Dipendenti della società. Le RSU hanno un prezzo di esercizio di $0 e matureranno al 100% alla prima delle seguenti date: (i) il primo anniversario della data di assegnazione oppure (ii) un Cambio di Controllo, a condizione che il direttore rimanga nel consiglio fino alla data di maturazione.

Dopo l’assegnazione, la proprietà diretta totale di Sepulveda è aumentata a 59.224 azioni ordinarie. Non sono stati segnalati titoli derivati né acquisti o vendite sul mercato aperto; si tratta di un premio azionario pensato per allineare gli incentivi del direttore con gli interessi degli azionisti. La transazione non influisce in modo significativo sul numero di azioni o sulla struttura del capitale di HilleVax, ma aumenta leggermente la proprietà interna.

HilleVax, Inc. (HLVX) presentó un Formulario 4 informando que el director externo Jaime Sepulveda 𳦾ó 17,199 unidades de acciones restringidas (RSU) el 23 de junio de 2025 bajo el Programa de Compensación para Directores No Empleados de la compañía. Las RSU tienen un precio de ejercicio de $0 y se consolidarán al 100% en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesión o (ii) un Cambio de Control, siempre que el director permanezca en la junta hasta la fecha de consolidación.

Tras la concesión, la propiedad directa total de Sepulveda aumentó a 59,224 acciones ordinarias. No se reportaron valores derivados ni compras o ventas en el mercado abierto; se trata de una concesión de acciones diseñada para alinear los incentivos del director con los intereses de los accionistas. La transacción no afecta materialmente el número de acciones ni la estructura de capital de HilleVax, pero incrementa ligeramente la propiedad interna.

HilleVax, Inc. (HLVX)� 비임� 이사 Jaime Sepulveda가 2025� 6� 23� 회사� 비임� 이사 보상 프로그램� 따라 17,199개의 제한 주식 단위(RSU)� 받았음을 공개하는 Form 4� 제출했습니다. � RSU� 행사가� $0이며, (i) 부여일로부� 1주년 또는 (ii) 경영� 변� � 빠른 시점� 100% 베스팅되�, 이사� 베스팅일 까지 이사회에 남아 있어� 합니�.

부� � Sepulveda� 직접 소유 주식 총수� 59,224 보통�� 증가했습니다. 파생 증권은 보고되지 않았�, 공개 시장에서� 매매� 없었습니�; 이는 이사� 인센티브� 주주 이익� 일치시키� 위한 주식 보상입니�. � 거래� HilleVax� 주식 수나 자본 구조� � 영향� 미치지 않지�, 내부� 소유� 약간 증가시킵니다.

HilleVax, Inc. (HLVX) a déposé un formulaire 4 révélant que le directeur non salarié Jaime Sepulveda a reçu 17 199 unités d'actions restreintes (RSU) le 23 juin 2025 dans le cadre du programme de rémunération des administrateurs non salariés de la société. Les RSU ont un prix d'exercice de 0 $ et seront acquises à 100 % à la première des dates suivantes : (i) le premier anniversaire de la date d'attribution ou (ii) un changement de contrôle, à condition que le directeur reste au conseil d'administration jusqu'à la date d'acquisition.

Suite à cette attribution, la détention directe totale de Sepulveda est passée à 59 224 actions ordinaires. Aucun titre dérivé n'a été déclaré, et aucune transaction sur le marché ouvert n'a eu lieu ; il s'agit d'une attribution d'actions visant à aligner les incitations des administrateurs sur les intérêts des actionnaires. Cette opération n'affecte pas de manière significative le nombre d'actions ou la structure du capital de HilleVax, mais augmente légèrement la participation des initiés.

HilleVax, Inc. (HLVX) reichte ein Formular 4 ein, in dem offengelegt wurde, dass der nicht geschäftsführende Direktor Jaime Sepulveda am 23. Juni 2025 17.199 Restricted Stock Units (RSUs) im Rahmen des Vergütungsprogramms für nicht geschäftsführende Direktoren des Unternehmens erhalten hat. Die RSUs haben einen Ausübungspreis von 0 $ und werden zu 100 % fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Gewährungsdatums oder (ii) einem Kontrollwechsel, vorausgesetzt, der Direktor bleibt bis zum Vesting-Datum im Vorstand.

Nach der Gewährung stieg Sepulvedas Gesamtbesitz an Stammaktien auf 59.224 Aktien. Es wurden keine Derivate gemeldet und kein Kauf oder Verkauf am offenen Markt getätigt; es handelt sich um eine Aktienzuteilung, die darauf abzielt, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen. Die Transaktion wirkt sich nicht wesentlich auf die Aktienanzahl oder Kapitalstruktur von HilleVax aus, erhöht jedoch leicht den Insiderbesitz.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU grant to director; neutral impact on valuation and dilution.

The 17,199-unit RSU award represents a typical annual equity grant for a biotechnology company of HilleVax’s size. At ~$10 share price, the notional value is roughly $170k—immaterial to market cap and dilution (<0.1% of shares outstanding). Vesting over one year or upon a change in control aligns board incentives without cash outlay. Because no shares were sold, the filing signals continued service commitment rather than insider sentiment on valuation. I classify the event as neutral for investors.

HilleVax, Inc. (HLVX) ha depositato un Modulo 4 comunicando che il direttore non dipendente Jaime Sepulveda ha ricevuto 17.199 unità azionarie vincolate (RSU) il 23 giugno 2025, nell'ambito del Programma di Compenso per Direttori Non Dipendenti della società. Le RSU hanno un prezzo di esercizio di $0 e matureranno al 100% alla prima delle seguenti date: (i) il primo anniversario della data di assegnazione oppure (ii) un Cambio di Controllo, a condizione che il direttore rimanga nel consiglio fino alla data di maturazione.

Dopo l’assegnazione, la proprietà diretta totale di Sepulveda è aumentata a 59.224 azioni ordinarie. Non sono stati segnalati titoli derivati né acquisti o vendite sul mercato aperto; si tratta di un premio azionario pensato per allineare gli incentivi del direttore con gli interessi degli azionisti. La transazione non influisce in modo significativo sul numero di azioni o sulla struttura del capitale di HilleVax, ma aumenta leggermente la proprietà interna.

HilleVax, Inc. (HLVX) presentó un Formulario 4 informando que el director externo Jaime Sepulveda 𳦾ó 17,199 unidades de acciones restringidas (RSU) el 23 de junio de 2025 bajo el Programa de Compensación para Directores No Empleados de la compañía. Las RSU tienen un precio de ejercicio de $0 y se consolidarán al 100% en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesión o (ii) un Cambio de Control, siempre que el director permanezca en la junta hasta la fecha de consolidación.

Tras la concesión, la propiedad directa total de Sepulveda aumentó a 59,224 acciones ordinarias. No se reportaron valores derivados ni compras o ventas en el mercado abierto; se trata de una concesión de acciones diseñada para alinear los incentivos del director con los intereses de los accionistas. La transacción no afecta materialmente el número de acciones ni la estructura de capital de HilleVax, pero incrementa ligeramente la propiedad interna.

HilleVax, Inc. (HLVX)� 비임� 이사 Jaime Sepulveda가 2025� 6� 23� 회사� 비임� 이사 보상 프로그램� 따라 17,199개의 제한 주식 단위(RSU)� 받았음을 공개하는 Form 4� 제출했습니다. � RSU� 행사가� $0이며, (i) 부여일로부� 1주년 또는 (ii) 경영� 변� � 빠른 시점� 100% 베스팅되�, 이사� 베스팅일 까지 이사회에 남아 있어� 합니�.

부� � Sepulveda� 직접 소유 주식 총수� 59,224 보통�� 증가했습니다. 파생 증권은 보고되지 않았�, 공개 시장에서� 매매� 없었습니�; 이는 이사� 인센티브� 주주 이익� 일치시키� 위한 주식 보상입니�. � 거래� HilleVax� 주식 수나 자본 구조� � 영향� 미치지 않지�, 내부� 소유� 약간 증가시킵니다.

HilleVax, Inc. (HLVX) a déposé un formulaire 4 révélant que le directeur non salarié Jaime Sepulveda a reçu 17 199 unités d'actions restreintes (RSU) le 23 juin 2025 dans le cadre du programme de rémunération des administrateurs non salariés de la société. Les RSU ont un prix d'exercice de 0 $ et seront acquises à 100 % à la première des dates suivantes : (i) le premier anniversaire de la date d'attribution ou (ii) un changement de contrôle, à condition que le directeur reste au conseil d'administration jusqu'à la date d'acquisition.

Suite à cette attribution, la détention directe totale de Sepulveda est passée à 59 224 actions ordinaires. Aucun titre dérivé n'a été déclaré, et aucune transaction sur le marché ouvert n'a eu lieu ; il s'agit d'une attribution d'actions visant à aligner les incitations des administrateurs sur les intérêts des actionnaires. Cette opération n'affecte pas de manière significative le nombre d'actions ou la structure du capital de HilleVax, mais augmente légèrement la participation des initiés.

HilleVax, Inc. (HLVX) reichte ein Formular 4 ein, in dem offengelegt wurde, dass der nicht geschäftsführende Direktor Jaime Sepulveda am 23. Juni 2025 17.199 Restricted Stock Units (RSUs) im Rahmen des Vergütungsprogramms für nicht geschäftsführende Direktoren des Unternehmens erhalten hat. Die RSUs haben einen Ausübungspreis von 0 $ und werden zu 100 % fällig am früheren Zeitpunkt von (i) dem ersten Jahrestag des Gewährungsdatums oder (ii) einem Kontrollwechsel, vorausgesetzt, der Direktor bleibt bis zum Vesting-Datum im Vorstand.

Nach der Gewährung stieg Sepulvedas Gesamtbesitz an Stammaktien auf 59.224 Aktien. Es wurden keine Derivate gemeldet und kein Kauf oder Verkauf am offenen Markt getätigt; es handelt sich um eine Aktienzuteilung, die darauf abzielt, die Anreize des Direktors mit den Interessen der Aktionäre in Einklang zu bringen. Die Transaktion wirkt sich nicht wesentlich auf die Aktienanzahl oder Kapitalstruktur von HilleVax aus, erhöht jedoch leicht den Insiderbesitz.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sepulveda Jaime

(Last) (First) (Middle)
C/O HILLEVAX, INC., 321 HARRISON AVE,
SUITE 500

(Street)
BOSTON MA 02118

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HilleVax, Inc. [ HLVX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/23/2025 A 17,199(1) A $0.00 59,224 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.
/s/ Paul Bavier, Attorney-in-Fact for Jaime Sepulveda 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many HLVX shares did director Jaime Sepulveda receive?

He was granted 17,199 restricted stock units on 23 Jun 2025.

What is the vesting schedule for the new RSUs reported in the HLVX Form 4?

100% vest on the first anniversary of the grant date or upon a Change in Control, whichever occurs first, subject to continued board service.

Did the transaction involve any cash purchase or sale of HLVX shares?

No. The RSUs were issued at $0 cost; there were no open-market purchases or sales.

What is Jaime Sepulveda’s total direct ownership after this grant?

His direct holdings increased to 59,224 common shares following the transaction.

Does the RSU grant materially dilute existing HLVX shareholders?

Dilution is immaterial; the award equals a fraction of one percent of shares outstanding.
HilleVax, Inc.

NASDAQ:HLVX

HLVX Rankings

HLVX Latest News

HLVX Latest SEC Filings

HLVX Stock Data

102.21M
30.11M
17.09%
76.93%
0.92%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BOSTON